Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

Rahmathulla G, Hovey EJ, Hashemi-Sadraei N, Ahluwalia MS.

Onco Targets Ther. 2013 Apr 15;6:371-89. doi: 10.2147/OTT.S38628. Print 2013.

2.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review.

PMID:
25242542
3.

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.

Chen R, Cohen AL, Colman H.

Curr Treat Options Oncol. 2016 Aug;17(8):42. doi: 10.1007/s11864-016-0418-0. Review.

PMID:
27334978
4.

Bevacizumab for the treatment of recurrent glioblastoma.

Chamberlain MC.

Clin Med Insights Oncol. 2011;5:117-29. doi: 10.4137/CMO.S7232. Epub 2011 May 2.

5.

Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.

Chamberlain MC.

Cancer. 2010 Sep 1;116(17):3988-99. doi: 10.1002/cncr.25256. Review.

6.

Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.

Cuneo KC, Vredenburgh JJ, Sampson JH, Reardon DA, Desjardins A, Peters KB, Friedman HS, Willett CG, Kirkpatrick JP.

Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):2018-24. doi: 10.1016/j.ijrobp.2010.12.074. Epub 2011 Apr 12.

7.

Antiangiogenic therapy for patients with recurrent and newly diagnosed malignant gliomas.

Shirai K, Siedow MR, Chakravarti A.

J Oncol. 2012;2012:193436. doi: 10.1155/2012/193436. Epub 2011 Jul 14.

8.

Treatment of recurrent high-grade gliomas.

Wen PY, Brandes AA.

Curr Opin Neurol. 2009 Dec;22(6):657-64. doi: 10.1097/WCO.0b013e32833229e3. Review.

PMID:
19770658
9.

Bevacizumab in high-grade gliomas: past, present, and future.

Curry RC, Dahiya S, Alva Venur V, Raizer JJ, Ahluwalia MS.

Expert Rev Anticancer Ther. 2015 Apr;15(4):387-97. doi: 10.1586/14737140.2015.1028376. Review.

PMID:
25797685
10.

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY.

Neurology. 2008 Mar 4;70(10):779-87. doi: 10.1212/01.wnl.0000304121.57857.38.

PMID:
18316689
11.

Phase II study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma.

Nagane M, Nishikawa R, Narita Y, Kobayashi H, Takano S, Shinoura N, Aoki T, Sugiyama K, Kuratsu J, Muragaki Y, Sawamura Y, Matsutani M.

Jpn J Clin Oncol. 2012 Oct;42(10):887-95. Epub 2012 Jul 27.

12.

[Monoclonal antibodies in high-grade gliomas].

Chekhonin IV, Leopold AV, Gurina OI, Semenova AV.

Vestn Ross Akad Med Nauk. 2014;(9-10):131-9. Review. Russian.

PMID:
25816654
13.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
14.

Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.

Grothey A, Ellis LM.

Cancer J. 2008 May-Jun;14(3):170-7. doi: 10.1097/PPO.0b013e318178d9de. Review.

PMID:
18536556
15.

Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.

Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY.

Neuro Oncol. 2010 Jun;12(6):603-7. doi: 10.1093/neuonc/nop073. Epub 2010 Feb 14.

16.

Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma.

Abrams DA, Hanson JA, Brown JM, Hsu FP, Delashaw JB Jr, Bota DA.

J Clin Neurosci. 2015 Jan;22(1):35-9. doi: 10.1016/j.jocn.2014.05.054. Epub 2014 Dec 4. Review.

PMID:
25481268
17.

Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.

Gururangan S, Fangusaro J, Poussaint TY, McLendon RE, Onar-Thomas A, Wu S, Packer RJ, Banerjee A, Gilbertson RJ, Fahey F, Vajapeyam S, Jakacki R, Gajjar A, Goldman S, Pollack IF, Friedman HS, Boyett JM, Fouladi M, Kun LE.

Neuro Oncol. 2014 Jan;16(2):310-7. doi: 10.1093/neuonc/not154. Epub 2013 Dec 4.

18.

Antiangiogenic therapies for high-grade glioma.

Norden AD, Drappatz J, Wen PY.

Nat Rev Neurol. 2009 Nov;5(11):610-20. doi: 10.1038/nrneurol.2009.159. Epub 2009 Oct 13. Review.

PMID:
19826401
19.

Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas.

de Groot JF, Yung WK.

Cancer J. 2008 Sep-Oct;14(5):279-85. doi: 10.1097/PPO.0b013e3181867bd6. Review.

PMID:
18836331
20.

Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas.

Gutin PH, Iwamoto FM, Beal K, Mohile NA, Karimi S, Hou BL, Lymberis S, Yamada Y, Chang J, Abrey LE.

Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):156-63. doi: 10.1016/j.ijrobp.2008.10.043. Epub 2009 Jan 23.

Supplemental Content

Support Center